Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIRATE: Phenylbutyrate for NGAL Reduction in Proteinuric CKD
NCT02343094Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Feb 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sodium phenylbutyrate in chronic kidney disease (CKD), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Urinary Lipocalin 2 to Creatinine Ratio at Day 28. Started Feb 2015; status: completed.
02
Drugs
sodium phenylbutyrate
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT02343094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02343094.